Scarica l'app Stockscreener
253.79
0.69%
-1.77
Dopo l'orario di chiusura:
253.79
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$255.56
Aprire:
$254.43
Volume 24 ore:
8.68M
Relative Volume:
1.09
Capitalizzazione di mercato:
$611.61B
Reddito:
$97.93B
Utile/perdita netta:
$21.04B
Rapporto P/E:
29.42
EPS:
8.6278
Flusso di cassa netto:
$17.80B
1 W Prestazione:
-3.77%
1M Prestazione:
-6.00%
6M Prestazione:
+8.37%
1 anno Prestazione:
+31.35%
Intervallo 1D:
$251.50
$255.56
Intervallo di 1 settimana:
$248.50
$262.44
Portata 52W:
$184.66
$281.07
Johnson Johnson Stock (JNJ) Company Profile
Nome
Johnson Johnson
Settore
Industria
Telefono
732-524-2455
Indirizzo
ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ
Compare JNJ vs LLY, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JNJ
Johnson Johnson
|
253.79 | 611.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
LLY
Lilly Eli Co
|
1,240.34 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
ABBV
Abbvie Inc
|
282.68 | 499.53B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
143.63 | 354.36B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.20 | 285.49B | 54.66B | 13.58B | 16.05B | 7.0171 |
Johnson Johnson Stock (JNJ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-02 | Ripresa | UBS | Buy |
| 2026-05-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2026-04-08 | Ripresa | TD Cowen | Buy |
| 2026-01-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-10-20 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-10-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-07-23 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-05-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-07-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-05-30 | Ripresa | Goldman | Neutral |
| 2024-04-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2023-12-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-12-01 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-05 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Hold |
| 2023-05-30 | Ripresa | Citigroup | Buy |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-01 | Iniziato | Guggenheim | Neutral |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-14 | Reiterato | BofA Securities | Neutral |
| 2022-06-22 | Iniziato | Daiwa Securities | Outperform |
| 2022-05-23 | Ripresa | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-03-16 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-15 | Reiterato | Citigroup | Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-05-28 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-28 | Downgrade | UBS | Buy → Neutral |
| 2020-04-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-11-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-10-16 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2019-10-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2019-07-12 | Ripresa | Credit Suisse | Outperform |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-01-23 | Reiterato | Barclays | Equal Weight |
| 2018-07-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-06-27 | Iniziato | Bernstein | Mkt Perform |
| 2018-04-23 | Reiterato | Citigroup | Neutral |
| 2018-04-18 | Reiterato | Stifel | Hold |
| 2018-01-24 | Reiterato | Stifel | Hold |
| 2018-01-12 | Reiterato | Wells Fargo | Outperform |
| 2018-01-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2017-10-18 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-18 | Reiterato | Stifel | Hold |
Mostra tutto
Johnson Johnson Borsa (JNJ) Ultime notizie
2 Industries Beyond AI With Long-Term Demand Drivers for 2027 - Zacks Investment Research
Johnson & Johnson’s Dividend Machine Is Running. Can Earnings Keep Up? - Yahoo Finance
Johnson & Johnson Reports 48-Week Tremfya Results in Phase 3 Crohn’s Disease Fistula Study - Yahoo
3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case. - The Motley Fool
Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal - Zacks Investment Research
Has Johnson & Johnson Stock Become A Different Bet? - Yahoo Finance
Johnson & Johnson (JNJ) Has Improved, but I’m Holding Off after the Rally - TipRanks
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research
Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead - Yahoo Finance
Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead - AOL.com
Zacks Investment Ideas feature highlights: Intuitive Surgical - Zacks Investment Research
Johnson & Johnson (NYSE:JNJ): Can Drug Advances Strengthen the S&P 500? - Kalkine Media
What Does Johnson & Johnson (JNJ) News Mean For Its Growth Case? - Simply Wall Street
JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law - The National Law Review
Should You Invest in This Dividend King on the Dip? - The Motley Fool
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy. - The Motley Fool
Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy. - The Motley Fool
Former J&J site cleared for £31m redevelopment - BBC
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside - Zacks Investment Research
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors - Yahoo Finance
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors - The Motley Fool
This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term - The Motley Fool
Dividend Roundup: Johnson & Johnson, Coca-Cola, Costco, CVS Health, and more - Seeking Alpha
Breakfast News: Week in Review - The Motley Fool
Breaking Down The Big 3 Investing Strategies - Zacks Investment Research
3 Companies Raising Guidance This Earnings Season - Zacks Investment Research
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? - Zacks Investment Research
Johnson & Johnson reports mixed Q3 earnings - Healthcare Brew
Where Could Johnson & Johnson’s Next Growth Come From? - Trefis
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
Johnson & Johnson CFO taps internal investment for medtech growth - CFO Dive
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research
Stock of the Day: Is this the Bottom for Johnson & Johnson? - TradingView
The Open Question Under Johnson & Johnson Stock’s Price - Trefis
Johnson & Johnson (JNJ) Stock Dropped, What Is Behind The Latest Attention? - Simply Wall Street
J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says - 24/7 Wall St.
JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges - Zacks Investment Research
Johnson & Johnson Reports Q3 2026 Results, Raises Full-Year Guidance - VisionMonday.com
Johnson & Johnson MedTech sets mid-2027 target for ortho spinoff, as Q3 device sales disappoint - MassDevice
UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? - Zacks Investment Research
UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? - Zacks Investment Research
Johnson & Johnson: Keep Calm And Hold On (NYSE:JNJ) - Seeking Alpha
J&J’s medtech business slows again in Q3 - MedTech Dive
Johnson & Johnson shares fall following earnings - CNBC
Johnson &Johnson Stock Earnings: Can a Spinoff Fix Its Medtech Problem - Barron's
Why Johnson & Johnson Stock Dropped Today - The Motley Fool
Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth - Morningstar
Why Johnson & Johnson Stock Dropped Today - Yahoo Finance
Johnson Johnson Azioni (JNJ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Johnson Johnson Azioni (JNJ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schmid Timothy | EVP, WW Chair, MedTech |
Sep 02 '26 |
Sale |
274.74 |
33,597 |
9,230,440 |
25,447 |
| Schmid Timothy | Officer |
Sep 02 '26 |
Proposed Sale |
274.74 |
33,597 |
9,230,440 |
0 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine |
Aug 17 '26 |
Sale |
263.36 |
15,000 |
3,950,400 |
194,451 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine |
Aug 17 '26 |
Option Exercise |
115.67 |
15,000 |
1,735,050 |
209,451 |
| Taubert Jennifer L | Officer |
Aug 17 '26 |
Proposed Sale |
263.36 |
15,000 |
3,950,418 |
0 |
| Duato Joaquin | CEO and Chairman of the Board |
Aug 13 '26 |
Option Exercise |
115.67 |
123,291 |
14,261,070 |
399,258 |
| Duato Joaquin | CEO and Chairman of the Board |
Aug 13 '26 |
Sale |
261.17 |
123,291 |
32,199,927 |
275,967 |
| Duato Joaquin | Officer |
Aug 13 '26 |
Proposed Sale |
261.17 |
123,291 |
32,199,927 |
0 |
| Forminard Elizabeth | EVP, Chief Legal Officer |
Aug 06 '26 |
Option Exercise |
131.94 |
9,344 |
1,232,847 |
32,912 |
| Forminard Elizabeth | EVP, Chief Legal Officer |
Aug 06 '26 |
Sale |
257.00 |
15,918 |
4,090,960 |
16,994 |
0.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):